patent.fyi
Applications  /  US 2026/0355183
United States Patent Application Publication

US 2026/0355183 A1

Published
Nov 12, 2026
Filed
Apr 19, 2024
Earliest date on the face
Apr 21, 2023
Classification
A61K 31/497
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Focal ablation with PKC inhibition

What ifWhat if microwave ablation supplies local tumor control while the regimen retains PKC inhibition?
Claim language“a cMet inhibitor”

Image guidance positions a microwave antenna inside a selected liver lesion. Microwave energy heats the lesion and a planned margin of surrounding tissue, while a systemic small molecule inhibits PKC.

1.1Immune targeting with PKC inhibition

What ifWhat if a T-cell engager targets melanoma cells while the regimen retains PKC inhibition?
Claim language“and administering a therapeutically effective amount of a cMet inhibitor”

A soluble bispecific protein binds a melanocyte-lineage peptide presented by a specific human leukocyte antigen and binds CD3 on T cells. This interaction directs T-cell killing toward cells that display the peptide, while a separate small molecule inhibits PKC.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Paired inhibition in tumor organoids

A laboratory assay applies PKC and c-MET inhibition to organoids derived from hepatic uveal melanoma metastases. Replicate wells contain organoids embedded in a three-dimensional hydrogel and receive vehicle, either inhibitor alone, or both inhibitors together. Automated microscopy measures organoid area over time, and an endpoint viability assay measures the fraction of cells that remain metabolically active.

Component substitution

Crizotinib as the c-met inhibitor

Crizotinib, a small molecule that inhibits c-MET kinase activity, serves as the c-MET inhibitor alongside a separately formulated PKC inhibitor. A hepatic metastasis cell assay compares the pair with matched single-agent and vehicle controls. The assay measures phosphorylated c-MET and a phosphorylated PKC substrate, alongside the corresponding total protein levels, to track activity at both targets.

Parameter or scale variation

Staggered exposure in hepatic tumor cultures

Parallel hepatic uveal melanoma cultures receive the two inhibitors simultaneously, receive the PKC inhibitor 24 hours before the c-MET inhibitor, or receive the c-MET inhibitor 24 hours before the PKC inhibitor. Each inhibitor remains in the culture medium after addition, and matched wells receive vehicle at the same handling times. Viability and target phosphorylation are measured immediately before the staggered second addition and 48 hours after both inhibitors are present.

Combination with existing systems

Dual inhibition in a perfused liver model

A microfluidic liver culture device places a hepatic uveal melanoma spheroid in a tissue chamber adjacent to a perfusion channel. A pump drives culture medium through the channel, and separate inlet reservoirs supply the PKC inhibitor and the c-MET inhibitor through a mixing junction upstream of the chamber. Inlet and outlet samples provide drug concentration measurements, and an optical window permits serial imaging of the spheroid.

Automated or data-driven variant

Automated measurement of hepatic tumor burden

Image analysis software processes baseline and follow-up contrast-enhanced liver scans acquired during treatment with the two inhibitors. A registration step aligns the scans, and a segmentation model generates editable masks for individual hepatic lesions. After a reviewer confirms the masks, the software records each lesion volume, sums the volumes by visit, and plots the total against treatment dates.

Robotic mapping of paired inhibitor responses

A liquid handler dispenses the PKC inhibitor along one axis of a multiwell plate and the c-MET inhibitor along the other axis to create a two-dimensional concentration matrix. Wells contain hepatic uveal melanoma cells, and the plate includes vehicle controls and concentration series for each inhibitor alone. A plate reader records viability, and analysis software normalizes the readings to the vehicle controls and maps the response at each concentration pair.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0155236 A1
Published
Jun 18, 2009
Filed
Aug 2, 2005
Class
A61K 38/45
Document BUS 11,116,759 B2
Published
Sep 14, 2021
Filed
Sep 26, 2018
Class
A61K 31/47
Claim 1
Document A
Document B
1.1administering a therapeutically effective amount of a PKC inhibitor and administering a therapeutically effective amount of a cMet inhibitor to the patient.
Treatment of a subject with a therapeutically effective amount of the peptide can include a single treatment or, preferably, can include a series of treatments.
A · US 2009/0155236 A1 · ¶ 117
The method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound that modulates MET.
B · US 11,116,759 B2 · ¶ 7

An empty cell means only that no passage was reproduced there.

Statements in these documents
This invention relates to amino acid sequences of annexin V and to the use of these sequences in the regulating cellular responses mediated by delta protein kinase C.
A · US 2009/0155236 A1 · ¶ 1
There remains a need in the art for therapeutic agents capable of regulating the activity of delta PKC, particularly for modulating the activity of delta PKC in its role associated with ischemia, in order to reduce the deleterious effects of ischemia and of reperfusion injury.
A · US 2009/0155236 A1 · ¶ 8
Thus, a need remains for methods of treating ocular melanoma, particularly by inhibiting MET.
B · US 11,116,759 B2 · ¶ 6
The melanoma can be ocular melanoma, and more particularly choroidal melanoma or iris melanoma.
B · US 11,116,759 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355183 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355183/, SHA-256 b6d06654afba33202ce651d9ea77a129afaf0b0b2e591e8dbf4df2272bb1a7ca
First published
Permanent addresshttps://patent.fyi/US20260355183/
Content fingerprint (SHA-256)b6d06654afba33202ce651d9ea77a129afaf0b0b2e591e8dbf4df2272bb1a7ca
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi